Search results
The Janssen COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID‑19 in people aged eighteen years and older. [36] [1] The vaccine is given by intramuscular injection into the deltoid muscle. The initial course consists of a single dose. [43]
- Who Can Take The Vaccine?
- Can Immunocompromised Persons Take The Vaccine?
- Should Pregnant Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- What’s The Recommended Dosage?
- Is It Safe?
- How Efficacious Is The Vaccine?
- Does It Work Against New Variants of Sars-Cov-2 Virus?
- Interchangeability Between Vaccine Products and Platforms
- Co-Administration with Inactivated Influenza Vaccines
The Janssen vaccine can be offered to people who have had COVID-19 in the past. But individuals may wish to choose to delay vaccination for 3 months following the infection.
Persons with immunocompromising conditions are at higher risk of severe COVID-19 and should be vaccinated. The WHO’s Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons can be viewed here. WHO recommends a second dose for all people with immunocompromising cond...
The Janssen vaccine is a nonreplicating vaccine. No safety issues have been identified following vaccination of more than 1,600 pregnant women using this vaccine platform for vaccines against other pathogens, such as the Ebola virus. Animal developmental and reproductive toxicity studies show no harm to the development of the foetus. WHO has identi...
Individuals with a history of anaphylaxis to any component of the vaccine should not take it. People who have had Thrombosis with thrombocytopenia (TTS) following the first dose of this vaccine should not receive a second dose of the same vaccine. Anyone with a body temperature over 38.5ºC should postpone vaccination until they no longer have a fev...
A single dose regimen, in keeping with the EUL recommendations for this vaccine, remains an acceptable option for countries, especially when faced with supply constraints and difficulties to reach remote populations. However, given the evidence demonstrating improved protection with a second dose, WHO recommends that all efforts should be taken to ...
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above. This vaccine has also undergone review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) and found to be safe for use. A rare serious adverse event is the “thrombosis wit...
Studies show that a second dose 2 months after the initial dose substantially increases efficacy, especially against symptomatic infections, including when caused by SARS-CoV-2 variants of concern. In the US, the vaccine efficacy of 2 doses, 2 months apart, was 94%. In comparison, the single dose vaccine efficacy in the USA was 72%. Furthermore, in...
SAGE has reviewed all available data on the performance of the vaccine in the settings of the variants of concern. In clinical trials this vaccine has been tested against a variety of SARS-CoV-2 virus variants, including B1.351 (first identified in South Africa) and P.2 (first identified in Brazil), and found to be efficacious. There are no data ye...
Evolving evidence suggests that heterologous COVID-19 vaccine schedules (using WHO EUL vaccine products from different platforms) may be more immunogenic and effective than homologous schedules, depending on the specific platforms and order of the products used. In particular, data shows that individuals who have received one dose of the Janssen va...
COVID-19 vaccines may be given concomitantly, or any time before or after, other adult vaccines including inactivated influenza vaccines. Different arms for injection should be used when both vaccines are delivered during the same visit. Continued pharmacovigilance monitoring is recommended.
May 28, 2021 · A single-dose Covid vaccine made by Janssen has been approved for use in the UK by the medicines regulator. The vaccine was 85% effective in stopping severe illness from Covid-19 in trials...
Jan 6, 2022 · The Janssen COVID-19 Vaccine also known as the Johnson & Johnson COVID-19 vaccine, is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Mar 23, 2021 · A: The Johnson & Johnson vaccine has shown to be very effective against COVID-19. In clinical trials, the vaccine was 85% protective against severe COVID-19. Additionally, four weeks after receiving the vaccine, no one died or was hospitalized due to COVID-19. This means that this vaccine is extremely effective at preventing severe and bad ...
Jan 29, 2021 · A new single-dose vaccine has shown to be 66% effective against Covid-19, and offered complete protection against hospitalisation and death in trials. However, there are signs the jab, made by...
Apr 19, 2024 · Quick Summary. Vaccine name: Ad26.COV2.S. Design type: Adenovirus viral vector. Dose number: 1 dose, with a “booster” dose recommended for all adults at least two months later. At least two...
